Log In
Print this Print this

Fluenz Tetra, FluMist Quadrivalent (MEDI-3250)

  Manage Alerts
Collapse Summary General Information
Company AstraZeneca plc
DescriptionIntranasal live attenuated influenza vaccine (LAIV) containing 2 strains of type A (H1N1 and H3N2) and 2 strains of type B (1 each from Yamagata and Victoria lineages)
Molecular Target
Mechanism of Action 
Therapeutic ModalityPreventive vaccine: Viral vaccine
Latest Stage of DevelopmentMarketed
Standard IndicationInfluenza virus
Indication DetailsPrevent seasonal influenza in children ages 24 months to less than 18 years; Prevent seasonal influenza in healthy children ages 2-8 years who have no contraindications or precautions; Prevent seasonal influenza in people ages 2 to 49 years old; Treat influenza virus
Regulatory Designation


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today